Skip to main content
Top
Published in: Current Rheumatology Reports 10/2015

01-10-2015 | Inflammatory Muscle Disease (Myositis) (R Aggarwal, Section Editor)

Myositis Mimics

Authors: E. Harlan Michelle, Andrew L. Mammen

Published in: Current Rheumatology Reports | Issue 10/2015

Login to get access

Abstract

Patients with autoimmune myositis typically present with muscle weakness, elevated serum levels of muscle enzymes, and abnormal muscle biopsies. However, patients with other acquired myopathies or genetic muscle diseases may have remarkably similar presentations. Making the correct diagnosis of another muscle disease can prevent these patients from being exposed to the risks of immunosuppressive medications, which benefit those with myositis, but not those with other types of muscle disease. Here, we review some of the most common acquired and inherited muscle diseases that can mimic autoimmune myositis, including inclusion body myositis, limb girdle muscular dystrophies, metabolic myopathies, mitochondrial myopathies, and endocrine myopathies. We emphasize aspects of the medical history, physical exam, laboratory evaluation, and muscle biopsy analysis that can help clinicians distinguish myositis mimics from true autoimmune myositis.
Literature
1.
go back to reference Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA. 2011;305(2):183-90. Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.  JAMA. 2011;305(2):183-90.
2.
go back to reference Furst DE, Amato AA, Iorga SR, et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve. 2012;45:676–83.CrossRefPubMed Furst DE, Amato AA, Iorga SR, et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve. 2012;45:676–83.CrossRefPubMed
3.
go back to reference Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord. 2012;13:1–13.CrossRef Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord. 2012;13:1–13.CrossRef
4.
go back to reference Theadom A, Rodrigues M, Roxburgh R, et al. Prevalence of muscular dystrophies: a systematic literature review. Neuroepidemiology. 2014;43:259–68.CrossRefPubMed Theadom A, Rodrigues M, Roxburgh R, et al. Prevalence of muscular dystrophies: a systematic literature review. Neuroepidemiology. 2014;43:259–68.CrossRefPubMed
5.
go back to reference Norwood FLM, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132:3175–86.PubMedCentralCrossRefPubMed Norwood FLM, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132:3175–86.PubMedCentralCrossRefPubMed
6.
go back to reference Cardamone M, Darras BT, Ryan MM. Inherited myopathies and muscular dystrophies. Semin Neurol. 2008;28:250–9.CrossRefPubMed Cardamone M, Darras BT, Ryan MM. Inherited myopathies and muscular dystrophies. Semin Neurol. 2008;28:250–9.CrossRefPubMed
7.
go back to reference Paltiel AD, Ingvarsson E, Lee DKK, et al. Demographic and clinical features of inclusion body myositis in North America. Muscle Nerve. 2015. doi:10.1002/mus.24562. Paltiel AD, Ingvarsson E, Lee DKK, et al. Demographic and clinical features of inclusion body myositis in North America. Muscle Nerve. 2015. doi:10.​1002/​mus.​24562.
8.•
go back to reference Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134:3176–84. This study demonstrates that immunosuppressive treatment does not benefit, and may actually harm, patients with IBM.CrossRefPubMed Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134:3176–84. This study demonstrates that immunosuppressive treatment does not benefit, and may actually harm, patients with IBM.CrossRefPubMed
9.
go back to reference Cortese A, Machado P, Morrow J, et al. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul Disord. 2013;23:404–12.CrossRefPubMed Cortese A, Machado P, Morrow J, et al. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul Disord. 2013;23:404–12.CrossRefPubMed
10.
go back to reference Benveniste O, Stenzel W, Hilton-Jones D, et al. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol. 2015;129:611–29.PubMedCentralCrossRefPubMed Benveniste O, Stenzel W, Hilton-Jones D, et al. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol. 2015;129:611–29.PubMedCentralCrossRefPubMed
11.
go back to reference Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134:3167–75.CrossRefPubMed Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134:3167–75.CrossRefPubMed
13.
go back to reference Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion body myositis. Neurology. 2006;66(2 Suppl 1):S123–4.CrossRefPubMed Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion body myositis. Neurology. 2006;66(2 Suppl 1):S123–4.CrossRefPubMed
14.
go back to reference Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(Pt 6):1536–44.PubMedCentralCrossRefPubMed Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(Pt 6):1536–44.PubMedCentralCrossRefPubMed
15.
go back to reference Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;3:323–7.CrossRef Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;3:323–7.CrossRef
16.
go back to reference Kosmidis ML, Alexopoulos H, Tzioufas AG, et al. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci. 2013;334:123–5.CrossRefPubMed Kosmidis ML, Alexopoulos H, Tzioufas AG, et al. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci. 2013;334:123–5.CrossRefPubMed
17.
go back to reference The Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology. 2004;63:718–20.CrossRef The Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology. 2004;63:718–20.CrossRef
18.
go back to reference Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis. Curr Rheumatol Rep. 2012;14:244–51.CrossRefPubMed Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis. Curr Rheumatol Rep. 2012;14:244–51.CrossRefPubMed
19.
go back to reference Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2009;10:178–84.CrossRefPubMed Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2009;10:178–84.CrossRefPubMed
20.
go back to reference Chahin N, Engel AG. Correlation of muscle biopsy, clinical course and outcome in PM and sporadic IBM. Neurology. 2008;70:418–24.CrossRefPubMed Chahin N, Engel AG. Correlation of muscle biopsy, clinical course and outcome in PM and sporadic IBM. Neurology. 2008;70:418–24.CrossRefPubMed
21.
go back to reference Girolamo F, Lia A, Amati A, et al. Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. Neuropathol Appl Neurobiol. 2013;39:736–49.CrossRefPubMed Girolamo F, Lia A, Amati A, et al. Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. Neuropathol Appl Neurobiol. 2013;39:736–49.CrossRefPubMed
22.
go back to reference Maurage CA, Bussiere T, Sergeant N, et al. Tau aggregates are abnormally phosphorylated in inclusion body myositis and have an immunoelectrophoretic profile distinct from other tauopathies. Neuropathol Appl Neurobiol. 2004;30:624–34.CrossRefPubMed Maurage CA, Bussiere T, Sergeant N, et al. Tau aggregates are abnormally phosphorylated in inclusion body myositis and have an immunoelectrophoretic profile distinct from other tauopathies. Neuropathol Appl Neurobiol. 2004;30:624–34.CrossRefPubMed
23.
go back to reference Vattemi G, Nogalska A, King Engel W, et al. Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis. Acta Neuropathol. 2009;117:569–74.CrossRefPubMed Vattemi G, Nogalska A, King Engel W, et al. Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis. Acta Neuropathol. 2009;117:569–74.CrossRefPubMed
24.
go back to reference Hori H, Yamashita S, Tawara N, et al. Clinical features of Japanese patients with inclusion body myositis. J Neurol Sci. 2014;346:133–7.CrossRefPubMed Hori H, Yamashita S, Tawara N, et al. Clinical features of Japanese patients with inclusion body myositis. J Neurol Sci. 2014;346:133–7.CrossRefPubMed
25.
go back to reference Cox FM, Reijnierse M, van Rijswijk CS, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology. 2011;50:1153–6.CrossRefPubMed Cox FM, Reijnierse M, van Rijswijk CS, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology. 2011;50:1153–6.CrossRefPubMed
26.
go back to reference Tasca G, Monforte M, De F, Tasca G, Monforte M, De Fino C, et al. MRI pattern recognition in sporadic inclusion body myositis. Muscle Nerve. 2015. 10.1002/mus.24661. Tasca G, Monforte M, De F, Tasca G, Monforte M, De Fino C, et al. MRI pattern recognition in sporadic inclusion body myositis. Muscle Nerve. 2015. 10.1002/mus.24661.
27.
go back to reference Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38:705–13.CrossRefPubMed Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38:705–13.CrossRefPubMed
28.
go back to reference Rose MR, ENMC IBM Working Group. 188th ENMC International Workshop: inclusion body myositis 2–4 December, 2011, Naarden, The Netherlands. Neuromuscul Disord. 2013;23:1044–55.CrossRefPubMed Rose MR, ENMC IBM Working Group. 188th ENMC International Workshop: inclusion body myositis 2–4 December, 2011, Naarden, The Netherlands. Neuromuscul Disord. 2013;23:1044–55.CrossRefPubMed
29.
go back to reference Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry. 2013;84:1240–6.CrossRefPubMed Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry. 2013;84:1240–6.CrossRefPubMed
30.•
go back to reference Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014;83:426–33. This study defines simple, sensitive, and specific diagnostic criteria for IBM.PubMedCentralCrossRefPubMed Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014;83:426–33. This study defines simple, sensitive, and specific diagnostic criteria for IBM.PubMedCentralCrossRefPubMed
31.
go back to reference Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity of autoantibodies to cytosolic 5’-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune disease. Ann Rheum Dis. 2015. 10.1136/annrheumdis-2014-206691. Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity of autoantibodies to cytosolic 5’-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune disease. Ann Rheum Dis. 2015. 10.1136/annrheumdis-2014-206691.
32.
go back to reference Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al. Cytosolic 5′-nucleotidase 1A is a common target of circulating autoantibodies in several autoimmune diseases. Arthritis Care Res. 2015. doi:10.1002/acr.22600. Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al. Cytosolic 5′-nucleotidase 1A is a common target of circulating autoantibodies in several autoimmune diseases. Arthritis Care Res. 2015. doi:10.​1002/​acr.​22600.
33.••
go back to reference Larman HB, Salajeghen M, Nazareno R, et al. Cytosolic 5-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73:408–18. This study (along with 34) shows that positive anti-NT5C1a testing may be an effective means of distinguishing IBM from PM.CrossRefPubMed Larman HB, Salajeghen M, Nazareno R, et al. Cytosolic 5-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73:408–18. This study (along with 34) shows that positive anti-NT5C1a testing may be an effective means of distinguishing IBM from PM.CrossRefPubMed
34.••
go back to reference Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;This study (along with 33) shows that positive anti-NT5C1a testing may be an effective means of distinguishing IBM from PM:397–407. This study (along with 33) shows that positive anti-NT5C1a testing may be an effective means of distinguishing IBM from PM.CrossRef Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;This study (along with 33) shows that positive anti-NT5C1a testing may be an effective means of distinguishing IBM from PM:397–407. This study (along with 33) shows that positive anti-NT5C1a testing may be an effective means of distinguishing IBM from PM.CrossRef
35.
go back to reference Jain A, Sharma MC, Sarka C, et al. Major histocompatibility complex class I and II detection as a diagnostic tool in idiopathic inflammatory myopathies. Arch Pathol Lab Med. 2007;131:1070–6.PubMed Jain A, Sharma MC, Sarka C, et al. Major histocompatibility complex class I and II detection as a diagnostic tool in idiopathic inflammatory myopathies. Arch Pathol Lab Med. 2007;131:1070–6.PubMed
36.
go back to reference van der Pas J, Hengstman GJD, ter Laak HJ, et al. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2004;75:136–9.PubMedCentralPubMed van der Pas J, Hengstman GJD, ter Laak HJ, et al. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2004;75:136–9.PubMedCentralPubMed
37.
go back to reference Rodriguez Cruz PM, Luo Y, Miller J, et al. An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscul Disord. 2014;24:1025–35.CrossRefPubMed Rodriguez Cruz PM, Luo Y, Miller J, et al. An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscul Disord. 2014;24:1025–35.CrossRefPubMed
39.
go back to reference Hiniker A, Daniels BH, Lee HS, et al. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun. 2013;1:29–42.PubMedCentralCrossRefPubMed Hiniker A, Daniels BH, Lee HS, et al. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun. 2013;1:29–42.PubMedCentralCrossRefPubMed
40.
41.
go back to reference Sacconi S, Salviati L, Desnuelle C. Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta. 1852;2015:607–14. Sacconi S, Salviati L, Desnuelle C. Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta. 1852;2015:607–14.
42.
go back to reference Archata K, Ishihara T, Fukunaga H, et al. Inflammatory response in facioscapulohumeral muscular dystrophy: immunocytochemical and genetic analyses. Muscle Nerve Suppl. 1995;2:556–66. Abstract Only. Archata K, Ishihara T, Fukunaga H, et al. Inflammatory response in facioscapulohumeral muscular dystrophy: immunocytochemical and genetic analyses. Muscle Nerve Suppl. 1995;2:556–66. Abstract Only.
43.
44.
go back to reference Frisullo G, Frusciante R, Nociti V, et al. CD8+ T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol. 2011;31:155–6.CrossRefPubMed Frisullo G, Frusciante R, Nociti V, et al. CD8+ T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol. 2011;31:155–6.CrossRefPubMed
45.
go back to reference Confalonieri P, Oliva L, Andretta F, et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol. 2003;142:130–6.CrossRefPubMed Confalonieri P, Oliva L, Andretta F, et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol. 2003;142:130–6.CrossRefPubMed
46.
go back to reference Amato AA, Brown RF. Dysferlinopathies. In: Amato AA, Griggs RC, editors. Handbook of clinical neurology vol 101. Elsevier Science; 2011. pp. 11-118. Amato AA, Brown RF. Dysferlinopathies. In: Amato AA, Griggs RC, editors. Handbook of clinical neurology vol 101. Elsevier Science; 2011. pp. 11-118.
47.
go back to reference Fanin M, Angelini C. Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol. 2002;28:461–70.CrossRefPubMed Fanin M, Angelini C. Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol. 2002;28:461–70.CrossRefPubMed
48.
go back to reference Gayathri N, Alefia R, Nolini A, et al. Dysferlinopathy: spectrum of pathological changes in skeletal muscle tissue. Indian J Pathol Microbiol. 2011;54:350–4.CrossRefPubMed Gayathri N, Alefia R, Nolini A, et al. Dysferlinopathy: spectrum of pathological changes in skeletal muscle tissue. Indian J Pathol Microbiol. 2011;54:350–4.CrossRefPubMed
49.
go back to reference Gallardo E, Sienza A, Illa I. LGMD 2A. In: Amato AA, Griggs RC editors. Handbook of clinical neurology vol 101. Elsevier Science; 2011. pp. 101-97. Gallardo E, Sienza A, Illa I. LGMD 2A. In: Amato AA, Griggs RC editors. Handbook of clinical neurology vol 101. Elsevier Science; 2011. pp. 101-97.
50.
go back to reference Schroder T, Fuchss J, Schneider I, et al. Eosinophils in hereditary and inflammatory myopathies. Acta Myol. 2013;32:148–53.PubMedCentralPubMed Schroder T, Fuchss J, Schneider I, et al. Eosinophils in hereditary and inflammatory myopathies. Acta Myol. 2013;32:148–53.PubMedCentralPubMed
51.
go back to reference Sundaram C, Uppin MS, Meero AK. Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies. Neurol India. 2008;56:363–7.CrossRefPubMed Sundaram C, Uppin MS, Meero AK. Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies. Neurol India. 2008;56:363–7.CrossRefPubMed
53.
go back to reference Hagemans MLC, Winkel LPF, van Doorm PA, et al. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128:671–7.CrossRefPubMed Hagemans MLC, Winkel LPF, van Doorm PA, et al. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128:671–7.CrossRefPubMed
54.
go back to reference Winkel LPF, Hagemans MLC, van Doorm PA, et al. The natural course of non-classic Pompe’s disease: a review of 225 published cases. J Neurol. 2005;252:875–84.CrossRefPubMed Winkel LPF, Hagemans MLC, van Doorm PA, et al. The natural course of non-classic Pompe’s disease: a review of 225 published cases. J Neurol. 2005;252:875–84.CrossRefPubMed
55.
go back to reference Angelini C. Spectrum of metabolic myopathies. Biochim Biophys Acta. 1852;2015:615–21. Angelini C. Spectrum of metabolic myopathies. Biochim Biophys Acta. 1852;2015:615–21.
56.
go back to reference Lucia A, Nogales-Gadea G, Perez M, et al. McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol. 2008;4:568–77.CrossRefPubMed Lucia A, Nogales-Gadea G, Perez M, et al. McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol. 2008;4:568–77.CrossRefPubMed
57.
go back to reference Lucia A, Ruiz JR, Santalla A, et al. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry. 2012;83:322–8.CrossRefPubMed Lucia A, Ruiz JR, Santalla A, et al. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry. 2012;83:322–8.CrossRefPubMed
59.
60.
go back to reference Duyff RF, Van den Bosch J, Laman DM, et al. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry. 2000;68:750–5.PubMedCentralCrossRefPubMed Duyff RF, Van den Bosch J, Laman DM, et al. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry. 2000;68:750–5.PubMedCentralCrossRefPubMed
61.
go back to reference Eslamiam F, Bahrami A, Aghamohammadzadeh N, et al. Electrophysiologic changes in patients with untreated primary hypothyroidism. J Clin Neurophysiol. 2011;28:323–8.CrossRef Eslamiam F, Bahrami A, Aghamohammadzadeh N, et al. Electrophysiologic changes in patients with untreated primary hypothyroidism. J Clin Neurophysiol. 2011;28:323–8.CrossRef
62.
go back to reference Khedr EM, El Toony LF, Tarkhan MN, et al. Peripheral and central nervous system alterations in hypothyroidism: electrophysiological findings. Neuropsychobiology. 2000;41:88–94.CrossRefPubMed Khedr EM, El Toony LF, Tarkhan MN, et al. Peripheral and central nervous system alterations in hypothyroidism: electrophysiological findings. Neuropsychobiology. 2000;41:88–94.CrossRefPubMed
63.
go back to reference Chowla J. Stepwise approach to myopathy in systemic disease. Front Neurol. 2011;2:1–10. Chowla J. Stepwise approach to myopathy in systemic disease. Front Neurol. 2011;2:1–10.
64.
go back to reference Anwar S, Gibofsky A. Musculoskeletal manifestations of thyroid disease. Rheum Dis Clin N Am. 2010;36:637–46.CrossRef Anwar S, Gibofsky A. Musculoskeletal manifestations of thyroid disease. Rheum Dis Clin N Am. 2010;36:637–46.CrossRef
Metadata
Title
Myositis Mimics
Authors
E. Harlan Michelle
Andrew L. Mammen
Publication date
01-10-2015
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 10/2015
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-015-0541-0